SIREN : 523897668
PHARMACIE TOUZET is a French company founded 16 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in HENDAYE (64700), this company of category PME shows in 2025 a revenue of 240 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 240 000 € | 240 000 € | 240 000 € | 240 000 € | N/C | N/C | N/C | N/C | N/C | 1 902 369 € |
| Net income | 33 435 € | 3 850 € | 116 197 € | -84 142 € | 1 891 539 € | -36 961 € | 354 922 € | -22 397 € | -38 781 € | 11 279 € |
| EBITDA | 59 825 € | 27 353 € | 141 906 € | -54 685 € | -133 744 € | -1 797 € | -2 774 € | -3 033 € | -4 622 € | 239 577 € |
| Net margin | 13.9% | 1.6% | 48.4% | -35.1% | N/C | N/C | N/C | N/C | N/C | 0.6% |
In 2025, PHARMACIE TOUZET achieves revenue of 240 k€. Revenue is declining over the period 2016-2025 (CAGR: -20.5%). Slight decline of 0% vs 2024. After deducting consumption (0 €), gross margin stands at 240 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 60 k€, representing 24.9% of revenue. Positive scissor effect: EBITDA margin improves by +13.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 33 k€, i.e. 13.9% of revenue. This profit can be retained or distributed to shareholders.
240 000 €
240 000 €
59 825 €
59 815 €
33 435 €
24.9%
The debt ratio (= Financial debt / Equity x 100) stands at 479%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 17%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 157.5 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 14.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
479.166%
17.232%
14.052%
157.51
In 2025, the debt ratio of PHARMACIE TOUZET (479.17) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of PHARMACIE TOUZET (17.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of PHARMACIE TOUZET (157.51) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 10.74. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 34.3x. Operating income very largely covers interest expenses: high safety margin.
10.743
34.33
In 2025, the liquidity ratio of PHARMACIE TOUZET (10.74) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2025, the interest coverage of PHARMACIE TOUZET (34.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 62 days. Excellent situation: suppliers finance 62 days of the operating cycle (retail model). WCR is negative (-13 days): operations structurally generate cash. Notable WCR improvement over the period (-100%), freeing up cash.
-8 587 €
0 j
62 j
0 j
-13 j
Based on 170 transactions of similar company sales (all years), the value of PHARMACIE TOUZET is estimated at 324 070 € (range 200 506€ - 526 470€). With an EBITDA of 59 825€, the sector multiple of 6.8x is applied. The price/revenue ratio is 0.71x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMACIE TOUZET with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of PHARMACIE TOUZET in 2025 is 240 k€.
Yes, PHARMACIE TOUZET generated a net profit of 33 k€ in 2025.
The headquarters of PHARMACIE TOUZET is located in HENDAYE (64700), in the department Pyrenees-Atlantiques.
The tax return of PHARMACIE TOUZET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMACIE TOUZET operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.